The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Orosur Mining drops on disappointing assays

Fri, 02nd Dec 2022 10:40

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Premier Miton Group PLC, up 14% at 104.00 pence, 12-month range 84.69p - 207.00p. Reports both profit and assets under management declined in the year ended September 30. The asset manager posts pretax profit of GBP14.9 million, down 15% from GBP17.5 million a year earlier. Assets under management at September 30 were GBP10.57 billion, down 24% from GBP13.93 billion. More positively, assets under management recover to around GBP11.3 billion at November 25 and the firm sees a return to net positive flows in its funds during the first two months of its current financial year. Chief Executive Mark O'Shea says the results are "resilient" despite tougher market conditions and adds the firm is "well-positioned" to achieve its long-term growth ambitions.

----------

Tern PLC, up 5.0% at 11.03 pence, 12-month range 6.60p - 18.89p. Notes that Device Authority Ltd has expanded its business and technology relationship with an existing "tier one" automotive supply chain customer, winning a contract value of over USD1.2 million over five years. Tern has a 54% stake in the internet of things technology firm. The contract is for the deployment of Device Authority's KeyScaler technology which provides identity management services.

----------

AIM - LOSERS

----------

Orosur Mining Inc, down 31% at 8.78 pence, 12-month range 7.03p - 19.00p. Reports disappointing assay results for four additional diamond holes at the Pepas and Pupino prospects at its Anza project in Colombia. The project is a joint venture with Colombian company Minera Monte Aguila. The assay results indicate the best grade of gold and silver was found at Pepas hole number 009. The results at Pepas 009 show lower levels of gold mineralisation than intersected in previous drilling. No significant results were found at the Pupino prospect. The firm adds it will now shift its focus to groundwork.

----------

ReNeuron Group PLC, down 18% at 18.35 pence, 12-month range 15.00p - 95.22p. Says that it has been investigating an equity raise with investors, but explains "unfavourable conditions" in small-cap equity markets meant this was not possible. Adds that, following a review of its cost base and planned initiatives, savings have been identified in order to extend the firm's cash runway until "at least the start of the fourth calendar quarter of 2023" to ensure the continued development of its technology platform. The stem cell and exosomes technology company also reports a narrowed loss in in the six months ended September 30. Pretax loss totals GBP3.8 million, narrowed from a loss of GBP6.0 million the year before. ReNeuron's revenue multiplies to GBP438,000 from GBP58,000 the year before.

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
4 Apr 2019 10:32

ReNeuron Shares Rise On Positive Data From Blindness Treatment Trial

LONDON (Alliance News) - Shares rose in ReNeuron Group PLC on Thursday after it reported positive efficacy in a phase one/two clinical trial of its hRPC cell therapy candidate for treating in the

Read more
18 Mar 2019 11:42

ReNeuron Group Starts Dosing Of Second Cohort In hRPC Study

LONDON (Alliance News) - ReNeuron Group PLC on Monday said it started dosing of the second cohort of patients in a phase II study of its hRPC cell therapy candidate in the blindness-causing of in

Read more
18 Mar 2019 11:33

ReNeuron Group begins dosing second cohort in hRPC study

(Sharecast News) - Cell-based therapeutics company ReNeuron Group updated the market on progress with the ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).

Read more
20 Feb 2019 09:47

ReNeuron Reports Positive Preliminary Data In US Retinal Trial

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday reported "significant improvement in vision" in the trial of its hRPC cell therapy candidate for retinal disease.ReNeuron

Read more
20 Feb 2019 08:21

ReNeuron storms on 'exciting' eye disease trial success

(Sharecast News) - ReNeuron Group bounded upward on Wednesday after reporting that its cell-based therapy is showing signs that it can improve the sight of patients suffering from retinitis pigmentosa, which causes blindness.

Read more
31 Jan 2019 09:55

ReNeuron upbeat on data around ease of exosome manufacture

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that new data relating to the manufacturing scale-up of its GMP produced, CTX-derived exosomes was being presented at a US forum on the manufacture of cell and gene therapies.

Read more
24 Jan 2019 12:16

ReNeuron Group Reports First Enrolled Patient In Stroke Clinical Trial

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it enrolled the first patient in its US Phase IIb clinical study of CTX stem cell therapy for stroke disability.The study is a 6

Read more
24 Jan 2019 09:46

First patient dosed in latest ReNeuron study of CTX cell therapy

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that the first patient has been treated in the US Phase IIb clinical study of its 'CTX' cell therapy candidate for stroke disability.

Read more
4 Jan 2019 07:59

ReNeuron Group to collaborate with unnamed US biopharmaceutical firm

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has signed a collaboration agreement with an unnamed US-based biopharmaceutical company to explore the use of its exosome technology platform as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy, it announced on Friday.

Read more
14 Dec 2018 12:07

ReNeuron narrows losses as development programmes continue

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group issued its interim results for the six months ended 30 September on Friday, reporting a reduced loss for the period of £5.32m, from £9.57m year-on-year.

Read more
7 Dec 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Monday 10 December Photo-Me InternationalHalf Year ResultsHollywood Bowl GroupFull Year

Read more
18 Oct 2018 12:42

Reneuron's stem cell technology could produce cancer-combating cells

(Sharecast News) - New data from a study by Reneuron has encouraged the company that its stem cell technology could be adapted to specifically attack cancerous cells.

Read more
18 Oct 2018 10:54

ReNeuron Reports New Positive Data Relating To CTX Stem Cell Platform

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said its CTX stem cell therapy candidate can be successfully re-programmed to a pluripotent state.Pluripotent state is an embryonic a

Read more
12 Sep 2018 14:44

ReNeuron pleased with progress on several therapy fronts

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its trading on Wednesday, as investors gathered for the firm's annual general meeting, announcing that following recent co-ordinating ethics committee approval, the first clinical site has now been initiated in the US Phase IIb study with its CTX cell therapy candidate for stroke disability.

Read more
12 Sep 2018 13:54

ReNeuron Expects To Enroll First Patient For Stroke Study Shortly

LONDON (Alliance News) - ReNeuron Group PLC said Wednesday it expects to enroll the first patient in its stroke disability study "shortly".The company said that the first clinical

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.